The Latest Breaking News from Novartis

Novartis Earnings Preview

Novartis (NYSE:NVS) is set to give its latest quarterly earnings report on Tuesday, 2022-04-26. Here's what investors need to know before the announcement. Analysts estimate that Novartis will report an earnings per share (EPS) of $1.44.

Benzinga · Apr 25, 2022

Medical regulator faces questions over board members’ links to drug firms

Concerns over potential conflicts of interest lead to calls for regulator’s policy to be strengthened

The Guardian - UK · Apr 17, 2022

Golden Cross Appears Before Novartis Investors

If history is any guide, there may be good fortune ahead for shares of Novartis (NYSE:NVS). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the stock.

Benzinga · Apr 14, 2022

The Daily Biotech Pulse: BioXcel's Igalmi Gets FDA Nod, Citius Spikes On Positive Phase 3 Data, Iovance Receives Positive Regulatory Feedback For Skin Cancer Therapy

Here's a roundup of top developments in the biotech space over the last 24 hours.

Benzinga · Apr 6, 2022

Novartis Highlights Four-Year Efficacy, Safety Data On Kesimpta In Multiple Sclerosis

Novartis AG (NYSE:NVS) announced new long-term data from the Phase 3 ASCLEPIOS 1/2 trials and the ALITHIOS open-label extension of Kesimpta (ofatumumab) in multiple sclerosis. The data demonstrated long-term efficacy and safety of Kesimpta with continued reduced risk of disability worsening in relapsing multiple sclerosis following up to four years of treatment.  Kesimpta…

Benzinga · Apr 5, 2022

Novartis, Dr. Reddy’s in exclusive sales pact for select products

400 Novartis employees to lose jobs due to resulting role redundancies 

The Hindu · Apr 2, 2022

FDA Approves Novartis' Pluvicto As First Targeted Radioligand Therapy For Prostate Cancer

The FDA approved Novartis AG's (NYSE:NVS) Pluvicto (lutetium Lu 177 vipivotide tetraxetan) to treat patients with a type of advanced prostate cancer that has spread to other parts of the body. Pluvicto is a targeted radioligand therapy for adult patients who have already undergone other anticancer treatments. The company said it had submitted…

Benzinga · Mar 24, 2022

The Daily Biotech Pulse: Novartis Prostate Cancer Drug Lands FDA Approval, Ligand Announces SPAC Deal To Spin Off Antibody Business, Lilly's Lung Cancer Therapy Hit With CRL

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga · Mar 24, 2022

Morning Brief: Top Stories Dominating Financial Media on Tuesday, March 22

CNBC

Benzinga · Mar 22, 2022

Novartis Suspends Some Investment, Business Activities In Russia

Novartis AG (NYSE:NVS) will suspend capital investments, media advertising, and other promotional activities in Russia but remain committed to providing access to its medicine there. "Novartis condemns the war in Ukraine," it said in a statement, adding that "while we remain committed to providing access to our medicine in Russia, we responsibly…

Benzinga · Mar 22, 2022